Beyond the Delivery Room: Data, Doulas, and Patient-Centered OB-GYN
MD Newsline
In this episode of MD Newsline, Dr. Dillon Bannis, an OB-GYN practitioner based in the South Side of Chicago, shares his insights on the evolving challenges and innovations in obstetric and gynecological care. Dr. Bannis explores how listening, collaboration, and technology are reshaping the patient experience—from prenatal care and delivery practices to addressing health disparities and integrating AI into medicine.
With a strong emphasis on patient-centered communication, interdisciplinary col
info_outline
Infant Feeding, Early Habits & Childhood Obesity: What Parents Need to Know
MD Newsline
In this episode of MD Newsline, Dr. Wanda Averhart, a general pediatrician and obesity medicine specialist, explores the complex causes and lifelong impacts of childhood obesity, emphasizing how early feeding practices, maternal health, and social disparities shape children's long-term outcomes.
Dr. Averhart provides a comprehensive look at how environmental, cultural, and biological factors contribute to rising obesity rates among children—especially in underrepresented communities. She discuss
info_outline
The Future of Myeloma: Quadruplets, CAR-T & Beyond
MD Newsline
In this episode of MD Newsline, Dr. Shaina A. Rozell, a hematologist-oncologist at Affiliate Oncology in Chicago, Illinois, explores the rapidly advancing field of multiple myeloma treatment. She discusses how quadruplet therapies, MRD monitoring, and novel immunotherapies like bispecific antibodies and CAR-T are transforming outcomes for patients. Dr. Rozell also examines disparities in access to care, the growing role of community practices in clinical trials, and the balance between extending survival
info_outline
HPV Throat Cancer Misdiagnoses And How Technology Shapes ENT Health
MD Newsline
In this episode of MD Newsline, Dr. Tonia L. Farmer, a board-certified otolaryngologist and head & neck surgeon, discusses the gaps in ENT care, the growing impact of HPV-related cancers, and the importance of education and early detection in improving outcomes—particularly for underserved communities. Drawing from years of practice, Dr. Farmer explores how social, behavioral, and environmental factors shape ENT health and shares insights on emerging research and technologies revolutionizing the field.
info_outline
Personalized Approaches to Metabolic Liver Disease and MASH Management
MD Newsline
In this episode of MD Newsline, Dr. Christopher Kaisa, Assistant Professor of Medicine in the Section of Gastroenterology, Hepatology, and Nutrition at the University of Chicago Medicine, provides an in-depth discussion on Metabolic Dysfunction-Associated Steatohepatitis (MASH) and the evolving strategies for its management. He explains the latest non-invasive diagnostic tools, pharmacologic advancements, and the importance of multidisciplinary care in improving outcomes for patients with metabolic liver
info_outline
What's Next in Diabetes Care: New Treatments and Tech Insights
MD Newsline
In this episode of MD Newsline, Dr. Rachael Sood, a diabetes nurse practitioner and certified diabetes care and education specialist from New Orleans, Louisiana, shares her insights from the 85th American Diabetes Association Scientific Sessions. As the founder of The Diabetes Collective, Dr. Sood discusses the evolution of diabetology—a specialized field focused solely on the identification, treatment, and management of diabetes across all patient populations.
info_outline
High-Risk Multiple Myeloma & Personalized Treatment
MD Newsline
In this episode of MD Newsline, Dr. Martin Kaiser, Consultant Hematologist at the Royal Marsden Hospital and Professor of Hematology at the Institute of Cancer Research, London, discusses groundbreaking advances in the diagnosis and management of high-risk multiple myeloma. Drawing insights from the OptiMUM trial and related studies, Dr. Kaiser explores how genetic profiling, long-term treatment intensity, and personalized approaches are transforming patient outcomes. He also examines the challenges of t
info_outline
Clinical Trials vs Real World Practice in Leukemia Treatment
MD Newsline
In this episode of MD Newsline, Dr. Mark R. Litzow, Professor of Medicine at the Mayo Clinic in Rochester, Minnesota, discusses the groundbreaking findings from the ECOG-ACRIN E1910 trial and the evolving role of immunotherapy in acute lymphoblastic leukemia (ALL). He explores how real-world evidence complements clinical trials, the challenges of standardizing measurable residual disease (MRD) testing, and the future of personalized treatment strategies in hematologic malignancies.
Dr. Litzow shares deep
info_outline
A New Way to Treat Adrenal Insufficiency with an Insulin Pump
MD Newsline
In this episode of MD Newsline, Dr. Sassan Mirfakhraee, adult endocrinologist and associate professor at the University of Texas Southwestern Medical Center, shares groundbreaking insights into the management of adrenal insufficiency. At the Endocrine 2025 conference, Dr. Mirfakhraee presented his research on utilizing insulin pumps to deliver hydrocortisone—an innovative off-label approach that is showing promising results for patients who remain symptomatic on oral therapy.
He explains how thi
info_outline
Fighting Bone Metastasis in Breast Cancer
MD Newsline
In this episode of MD Newsline, we welcome Dr. Emily Zboril, a PhD candidate at Virginia Commonwealth University, to discuss her groundbreaking research on ER-positive breast cancer with bone metastasis. Emily sheds light on the unique challenges of treating this condition, the role of the bone microenvironment, and how novel therapies like lazophoxifene may change the landscape of care.
She explains how endocrine therapies currently used to block estrogen signaling often worsen bone fragility, leading t
info_outlineIn this episode of MD Newsline, Dr. Eleonora Teplinksy, a breast and gynecologic medical oncologist at Valley Health System and clinical assistant professor at the Icahn School of Medicine at Mount Sinai, shares key updates from the ASCO annual meeting. She discusses transformative clinical trials that are reshaping the landscape of metastatic breast cancer treatment across subtypes including hormone receptor-positive, HER2-positive, and triple-negative breast cancer.
Dr. Teplinksy highlights the promise of early mutation detection, the potential of antibody-drug conjugates, and the power of liquid biopsies. She also addresses pressing concerns around clinical trial diversity, treatment access, and the need for multidisciplinary care.
Episode Highlights:
Early Detection in HR+ Breast Cancer: The SERENA-6 Trial The SERENA-6 trial investigates whether switching to camizestrant—an oral SERD—upon early ESR1 mutation detection via liquid biopsy (before radiographic progression) improves progression-free survival. The study showed a 56% reduction in disease progression risk. However, issues around FDA approval, cost, testing frequency, and racial representation remain key concerns.
Advancing Triple-Negative Breast Cancer Care: ASCENT-04 The ASCENT-04 trial evaluates sacituzumab govitecan plus pembrolizumab vs. standard chemo-immunotherapy in PD-L1+ patients. Results revealed improved PFS (7.8 to 11.2 months), showing promise for first-line triple-negative treatment, though insurance coverage may delay clinical implementation.
HER2+ Breast Cancer Innovation: DESTINY-Breast09 This trial demonstrated that combining T-DXd with pertuzumab improved PFS from 26.9 to 40 months, suggesting a new standard for HER2+ metastatic breast cancer. Still, side effects like interstitial lung disease and lack of clarity on endocrine therapy integration must be addressed.
Real-World Barriers: Cost, Toxicity, and Care Access Dr. Teplinksy emphasizes challenges patients face—from time toxicity to insurance denials—and calls for thoughtful side-effect management and patient-centered treatment planning.
Multidisciplinary Collaboration and Future of AI in Oncology She underlines the role of interdisciplinary care and the need to bridge gaps across specialties. With AI and machine learning emerging, Dr. Teplinksy envisions more tailored treatments driven by biomarkers and real-world insights.
Key Takeaway
Dr. Teplinksy stresses the importance of early intervention, clinical trial equity, and multidisciplinary care in improving breast cancer outcomes. As the field embraces antibody-drug conjugates and AI-driven personalization, collaboration and access must evolve in step.
ResourcesWebsite: https://mdnewsline.com/ Newsletter: https://mdnewsline.com/subscribe/ Connect with Dr. Eleonora Teplinksy: Here
Hosted on Acast. See acast.com/privacy for more information.